



January 31, 2022

Subject: SUPPLY CONSTRAINTS FOR LANTUS® SOLOSTAR® (Insulin glargine) AND LANTUS® CARTRIDGES (Insulin glargine)

Dear Healthcare Professional,

Sanofi-aventis Canada Inc would like to inform you that Lantus® SoloSTAR® (insulin glargine) and Lantus® cartridges (insulin glargine) will be on supply constraint until March 21, 2022 due to a supply delay. We are working diligently with our distributors to minimize the impact on patients. All dosage forms for Lantus® will be on allocation based on your historical weekly sales. The table below indicates the estimated availability date.

| DIN | UPC | PRODUCT | FORMAT | STATUS | |
|----------|--------------|--------------------|--------|--------------------------|-----------------------------|
| | | | | Estimated depletion date | Estimated availability date |
| 02294338 | 065914110795 | Lantus® SoloSTAR® | 5 | Supply constraint | March 21, 2022 |
| 02251930 | 065914110221 | Lantus® cartridges | 5 | Supply constraint | March 21, 2022 |

Availability dates at a customer's usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.

We recognize the difficulties that this situation may cause for patients and health care providers and apologize for any inconvenience resulting from this.

All efforts are being made to resolve the situation, and any update will be communicated on the www.drugshortagescanada.ca website. Should you have any questions regarding this situation, please do not hesitate to call Customer Service at 1-800-265-7927.

Sincerely,

Hugues Corbeil
Marketing Manager, Portfolio Development